Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.37 |
| ▸ | HTR3B | O95264 | 4/20 | 0.37 |
| ▸ | HTR3A | P46098 | 4/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487262 | 0.92 | DGAT1 (0.42) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL6488011 | 0.91 | USP30 (0.47) | USP30DGAT1CHRNA7HTR3EHTR3B | |
| SCHEMBL6502998 | 0.87 | USP30 (0.48) | USP30DGAT1CHRNA7HTR3EHTR3B | |
| SCHEMBL6496913 | 0.87 | USP30 (0.57) | USP30DGAT1CHRNA7HTR3EHTR3B | |
| SCHEMBL6488741 | 0.86 | CHRNA7 (0.52) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL6502678 | 0.86 | USP30 (0.48) | USP30DGAT1CHRNA7HTR3EHTR3B | |
| SCHEMBL6499525 | 0.86 | USP30 (0.48) | USP30DGAT1CHRNA7HTR3EHTR3B | |
| SCHEMBL6487575 | 0.86 | USP30 (0.48) | USP30DGAT1CHRNA7HTR3EHTR3B | |
| SCHEMBL6486645 | 0.85 | USP30 (0.48) | USP30DGAT1CHRNA7TRPV1HTR3E | |
| SCHEMBL6495239 | 0.85 | USP30 (0.39) | USP30DGAT1CHRNA7HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | claimed |
| EP-1442041-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-04 | — | — | EP | claimed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| WO-2003040147-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | claimed |
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | NPC1 224/4885RAB9A 1437/4885PAX8 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.